In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
article
Chief executive Paul Hudson presented an upbeat results statement for Sanofi Friday morning, highlighting strong performance in the third quarter and a range of clinical developments under way. 28 October 2022
Biotechnology
The latest in a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological. 28 October 2022
Pharmaceutical
The pharmaceutical industry in Europe has questioned measures aimed at improving the way wastewater is treated by countries within the European Union. 28 October 2022
Biotechnology
Gilead Sciences announced its financial results for the third quarter of 2022 after markets closed yesterday, but the US biotech major’s shares were up 4.8% at $73.58 pre-market today. 28 October 2022
Biotechnology
Markets seemed unfazed, as GSK’s (LSE: AZN) shares barely moved on the news yesterday that it was discontinuing a development program for otilimab, as a result of mediocre performance of the drug in rheumatoid arthritis. 28 October 2022
Biotechnology
The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of moderate to severe atopic dermatitis submitted by Almirall. 28 October 2022
Pharmaceutical
Shares in Merck & Co were nearly 2% higher at lunchtime Thursday after the US pharma giant presented its third quarter 2022 financial results. 27 October 2022
Pharmaceutical
Ipsen has reported a 16% rise in its revenue for the third quarter of 2022. 27 October 2022
Biotechnology
US immuno-oncology cell therapy company 2seventy bio’s shares gained 3.5% to $16.00 this morning, as it announced a strategic alliance with Chinese biotech JW Therapeutics. 27 October 2022
Biotechnology
Positive top-line results from two global Phase III studies, BALATON and COMINO, evaluating the first and only bispecific antibody for the eye, Vabysmo (faricimab), in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) were released today by Swiss pharma giant Roche. 27 October 2022
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical’s shares edged 1.8% higher to $12.97 in early US trading, after it reported financial results for the first half of its fiscal year ended September 2022. 27 October 2022
Biotechnology
Anglo-Swedish pharma major AstraZeneca has presented new results on Ultomiris (ravulizumab) in neuromyelitis optica spectrum disorder (NMOSD). 27 October 2022
Pharmaceutical
A fairly positive outcome from a meeting of the US regulator’s scientific panel raises the prospect that pharma major GSK may be able to succeed where its British counterpart AstraZeneca has failed. 27 October 2022
Pharmaceutical
Rare diseases specialist Swedish Orphan Biovitrum saw its shares fall more than 3% to 204.40 kronor this morning after releasing third-quarter 2022 financial result. 27 October 2022
Generics
The US Food and Drug Administration (FDA) yesterday released its fiscal year (FY) 2023 Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives. 27 October 2022
Pharmaceutical
In the USA, the Biden-Harris Administration has made expanding access to health insurance and lowering health care costs for America’s families a top priority, and, starting now, consumers can preview their health care coverage options and see the savings available to them in the most competitive Marketplace in history. 27 October 2022
Biotechnology
The questions that were posed to the biopharmaceutical industry in 2020 were more urgent than ever before, as the COVID-19 pandemic brought much of the world to a standstill. 27 October 2022
Biotechnology
A US regulatory submission from microbiome company Seres Therapeutics has been accepted, with an expected decision date of April 26, 2023. 26 October 2022
Biotechnology
Australia’s largest biotech CSL Limited today revealed it has entered into a strategic option and license agreement with Arizona, USA-based Translational Sciences for rights to its enhanced thrombus (blood clot) dissolving drug candidate, TS23. 26 October 2022
Biotechnology
German-born UK resident Volker Hirsch has joined the Medicines Discovery Catapult (MDC) as chief commercial officer. 26 October 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze